Literature DB >> 28324163

New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch.

Takumi Fukumoto1, Masahiro Kido2, Atsushi Takebe2, Motofumi Tanaka2, Hisoka Kinoshita2, Kaori Kuramitsu2, Shohei Komatsu2, Daisuke Tsugawa2, Tadahiro Goto2, Sadaki Asari2, Hirochika Toyama2, Tetsuo Ajiki2, Yonson Ku2.   

Abstract

PURPOSE: Patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) invading the portal trunk (Vp4) are poor surgical candidates because of the technical difficulties involved. To overcome the limitations, we developed a technique of back-flow thrombectomy (BFT) based on the inherent portal hemodynamics and the macroscopic form of PVTT.
METHODS: Forty-six patients with multiple HCC and Vp4 PVTT underwent hepatectomy with tumor thrombectomy. We used the BFT to treat 24 patients, 18 of whom had PVTT in the contralateral second portal branch. The form of PVTT was classified macroscopically into the floating and expansive types.
RESULTS: The rate of complete removal by BFT of PVTT in the contralateral second portal branch was 89%. The patency rates at the thrombectomy site in all 46 patients and in the 24 BFT patients, 3 months after hepatectomy were 93 and 90%, respectively. The median OS of all 46 patients was 15 months, with 1- and 3-year OS rates of 58.5 and 17.1%, respectively. The median OS of the 24 patients treated with BFT vs. the 22 not treated with BFT was 14 and 15 months, respectively.
CONCLUSIONS: BFT can expand the therapeutic time window for patients with HCC and deep-seated PVTT and may improve their survival.

Entities:  

Keywords:  Back flow thrombectomy; Hepatectomy; Hepatocellular carcinoma; Portal vein tumor thrombus

Mesh:

Year:  2017        PMID: 28324163     DOI: 10.1007/s00595-017-1507-9

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  37 in total

1.  A new classification for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Jie Shi; Eric C H Lai; Nan Li; Wei-Xing Guo; Jie Xue; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-01       Impact factor: 7.027

2.  Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein.

Authors:  Iwao Ikai; Etsuro Hatano; Suguru Hasegawa; Hideaki Fujii; Kojiro Taura; Naoki Uyama; Yasuyuki Shimahara
Journal:  J Am Coll Surg       Date:  2006-01-20       Impact factor: 6.113

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.

Authors:  E Villa; A Moles; I Ferretti; P Buttafoco; A Grottola; M Del Buono; M De Santis; F Manenti
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Single catheter technique of hepatic venous isolation and extracorporeal charcoal hemoperfusion for malignant liver tumors.

Authors:  Y Ku; T Fukumoto; M Tominaga; T Iwasaki; I Maeda; N Kusunoki; H Obara; M Sako; Y Suzuki; Y Kuroda; Y Saitoh
Journal:  Am J Surg       Date:  1997-02       Impact factor: 2.565

7.  Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein.

Authors:  Y Yamaoka; K Kumada; K Ino; T Takayasu; Y Shimahara; K Mori; A Tanaka; T Morimoto; Y Taki; M Washida
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

8.  Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival.

Authors:  Chi-Sin Changchien; Chao-Long Chen; Yi-Hao Yen; Jing-Houng Wang; Tsung-Hui Hu; Chuan-Mo Lee; Chih-Chi Wang; Yu-Fan Cheng; Yu-Jie Huang; Chih-Yun Lin; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2008-02-29       Impact factor: 7.527

9.  Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma.

Authors:  Y Ku; T Fukumoto; T Iwasaki; M Tominaga; M Samizo; T Nishida; Y Kuroda; S Hirota; M Sako; H Obara
Journal:  Surgery       Date:  1995-05       Impact factor: 3.982

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

1.  Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report.

Authors:  Kazuhiro Takahashi; Jaejeong Kim; Amane Takahashi; Shinji Hashimoto; Manami Doi; Kinji Furuya; Ryosuke Hashimoto; Yohei Owada; Koichi Ogawa; Yusuke Ohara; Yoshimasa Akashi; Katsuji Hisakura; Tsuyoshi Enomoto; Osamu Shimomura; Masayuki Noguchi; Tatsuya Oda
Journal:  World J Hepatol       Date:  2021-03-27

Review 2.  Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers.

Authors:  Lucia Cerrito; Brigida Eleonora Annicchiarico; Roberto Iezzi; Antonio Gasbarrini; Maurizio Pompili; Francesca Romana Ponziani
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.